First Human Trial of AI-Designed Bacteriophages Conducted in San Francisco
A groundbreaking experiment has seen AI-engineered bacteriophages administered to a patient with antibiotic-resistant infection, marking a significant milestone in medical research.
Radical Numerics has administered AI-designed bacteriophages to a human patient, a world first.
The treatment was authorized under a compassionate-use pathway by the FDA, but results remain undisclosed.
Concerns about safety and efficacy persist as the medical community awaits peer-reviewed findings.
In a pioneering medical development, Radical Numerics, a San Francisco-based lab, has reported administering AI-engineered bacteriophages to a human patient suffering from a drug-resistant bacterial infection. This unprecedented trial, which occurred in October 2026, is the first instance of an AI-designed organism being used as a therapeutic intervention in a clinical setting, potentially revolutionizing the treatment of antibiotic-resistant infections.
Bacteriophages, viruses that specifically target bacteria, have been utilized in medical treatments for over a century. However, their application has gained renewed interest as antibiotic resistance becomes a growing global health crisis. The World Health Organization has recognized phage therapy as generally safe, offering a targeted approach that spares beneficial bacteria while combating harmful strains. The challenge lies in identifying the right phage for each specific bacterial infection, a process that can be time-consuming and critical for patients in severe conditions.
Radical Numerics developed its Omnii-1 model to create bacteriophages by modifying the genetic structure of existing phages, specifically targeting the receptor-binding components. The company claims that their engineered phages showed a high success rate in laboratory tests against bacteria isolated from the patient’s infection. However, the details of the patient's clinical outcome and treatment progression remain undisclosed, as the company cites patient privacy concerns.
The implications of this trial extend beyond individual patient care, as the rise of antibiotic-resistant infections poses a significant threat to public health. The Global Burden of Disease project estimates that antimicrobial resistance was linked to approximately 4.7 million deaths in 2021, with projections suggesting that this figure could rise dramatically in the coming decades. If successful, AI-designed phage therapy could offer a new avenue for treating infections that currently have limited options.
Looking ahead, Radical Numerics plans to publish its findings through peer review, although skepticism remains among experts regarding the treatment's safety and efficacy. As the medical community awaits more comprehensive data, the potential for AI to expedite the design and application of phage therapies could reshape the landscape of infectious disease treatment, provided that ethical and safety measures are rigorously upheld.
